TIDMPOLB
RNS Number : 2931E
Poolbeg Pharma PLC
29 June 2023
Poolbeg Pharma plc
Successful Artificial Intelligence led programme identifies
multiple influenza drug targets
AI analysis of unique human challenge trial data provides
unparalleled insights into influenza infection
Novel influenza drug targets identified faster and more
cost-effectively using AI
29 June 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company focusing on infectious and other prevalent diseases with a
high unmet medical need, announces a significant breakthrough in
its world first influenza Artificial Intelligence ('AI') Programme
with CytoReason . Poolbeg has been working with CytoReason since
March 2022.
Poolbeg's unique disease progression data from influenza human
challenge trials combined with CytoReason's broad repositories of
curated disease data were analysed using CytoReason's
industry-leading AI-led platform. The analysis has led to the
discovery of multiple novel drug targets for the treatment of
influenza.
Identification of drug targets from this unique data-set has
previously been successful as p38 MAP Kinase, inhibited by POLB
001, was identified as a driver of severe influenza but this
required manual analysis that took several years. However, through
the utilisation of CytoReason's cutting-edge AI technology, Poolbeg
has now identified multiple novel drug targets in just 15 months.
Moreover, CytoReason's analysis independently confirmed the
significance of the p38 MAP kinase pathway in influenza, providing
further validation for Poolbeg's POLB 001 programme.
The Company is actively exploring the most effective way to
further develop the novel drug targets in order to generate value
and looks forward to updating shareholders about the progress of
this programme in due course. This marks Poolbeg's second
successful AI Programme, following the identification of potential
new drug candidates for Respiratory Syncytial Virus (RSV) announced
in December 2022 .
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, commented: "Our collaboration with CytoReason has put
Poolbeg at the forefront of AI drug discovery. CytoReason's deep
interrogation of the uniquely rich data derived from human
challenge trials has deepened our knowledge of influenza, resulting
in the identification of multiple novel influenza drug targets.
There is a significant unmet need for new and better treatments for
vulnerable patients with influenza and this is a major milestone in
the delivery of new therapies that can improve patient outcomes and
global health."
David Harel, Chief Executive Officer of CytoReason, said:
"Once again, we're pleased to see that leveraging CytoReason's
computational disease models to extract insight s from Poolbeg's
unique human challenge data can optimise the target discovery
process. More importantly, t hese impressive results would not be
possible without the commitment, transparen cy , and reciproc ity
of both teams ."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser &
Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
Further detail on the power of human challenge trial data
Poolbeg Pharma has access to a unique repository of clinical
samples and associated data from human challenge trials. Data from
human challenge trials are unique in that they track a healthy
subject through disease to recovery in carefully controlled and
monitored isolation units, collecting samples throughout the course
of disease, and vitally collecting matched baseline and follow-up
samples before and after infection. This data is unique in the
depth of longitudinal virology, health, biomarker and symptom data
collected during the course of disease.
About Influenza
Influenza is a viral pathogen that infects approximately
one-eighth of the world's population each year, an estimated 1
billion people are infected globally, attacking the respiratory
system and leading to between 5 and 10 million hospitalisations and
as many as 500,000 influenza related deaths. Survivors of influenza
can suffer organ damage, leading to chronic and life-changing
injuries.
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg has a disciplined portfolio approach to
mitigate risk, accelerate drug development, and enhance investor
returns. The Company simultaneously advances multiple programmes in
cost-effective clinical trials, rapidly generating early human
safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg also uses AI to interrogate human challenge trial data sets
to quickly identify new targets and drugs, and in-license near or
in the clinic medicines, leading to faster development and greater
commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc (formerly Open Orphan
plc), an industry leading infectious disease and human challenge
trials business, Poolbeg has access to knowledge, experience, and
clinical data from over 20 years of human challenge trials. The
Company is using these insights to acquire new assets as well as
reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza and other acute
inflammatory conditions (POLB 001) which produces a highly
significant reduction in p38 MAP kinase driven cytokines in a
clinical setting; a first-in-class, intranasally administered
RNA-based immunotherapy for respiratory virus infections (POLB
002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is also developing two O ral Delivery Programmes and is
progressing two A rtificial I ntelligence (AI) P rogrammes to add
promising new assets to its pipeline.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
About CytoReason
CytoReason is a tech company developing computational disease
models. With CytoReason's innovative technology and top-tier
science, pharma and biotech companies identify new opportunities,
shorten trial phases, reduce development costs, and increase the
likelihood of drug approval. Multiple stakeholders in the
organization rely on CytoReason to make data-driven decisions.
Scientists can identify targets and prioritize indications.
Managers can compare one drug across several diseases, or multiple
drugs across one disease. And C-level executives can manage entire
drug portfolios. CytoReason was founded in 2016 and is
headquartered in Tel Aviv. For more information, visit
www.cytoreason.com or follow us on LinkedIn or Twitter .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUAWQUPWGQR
(END) Dow Jones Newswires
June 29, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024
